Literature DB >> 26184635

Inhibition of Poly-(ADP-Ribose) Polymerase Protects the Kidney in a Canine Model of Endotoxic Shock.

Si-bo Liu1, Jinjie Liu, Da-wei Liu, Xiao-ting Wang, Rong-li Yang.   

Abstract

Poly-(ADP-ribose) polymerases (PARPs), a super family of enzymes, play important roles in preserving genomic integrity, regulating transcriptions, protecting telomeres and determining cell fate. PARP overactivation leads to metabolic disorder and cell injury via depletion of energy substance. However, it is still unclear whether PARP overactivation happens during acute kidney injury (AKI) caused by endotoxic shock (ES). Here, we built a canine model of lipopolysaccharide-induced ES to explore the role of PARP during the development AKI. We also used an intravenous injection of 3-aminobenzamide (3-AB) to further explore whether PARP inhibition rescues the kidney from injury. Cell fate and energy metabolism were detected to explore the underlying mechanisms. As a result, Western blot and immunohistochemistry assays showed PARP overactivation in the very early phase of ES. Through PARP inhibition by 3-AB, we observed significant improvement of systemic hemodynamics, renal hemodynamics, renal oxygen metabolism and renal tubular cell apoptosis. These findings indicated that overactivation of PARP plays an important role in septic AKI. Inhibition of PARP overactivation may protect renal function against hemodynamic disorder, renal metabolism disturbance and renal cell apoptosis during endotoxic AKI.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26184635     DOI: 10.1159/000435815

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

1.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

Review 2.  Molecular Mechanisms of Parthanatos and Its Role in Diverse Diseases.

Authors:  Ping Huang; Guangwei Chen; Weifeng Jin; Kunjun Mao; Haitong Wan; Yu He
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 3.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 4.  Innovations and Emerging Therapies to Combat Renal Cell Damage: NAD+ As a Drug Target.

Authors:  Carlos L Manrique-Caballero; John A Kellum; Hernando Gómez; Francesca De Franco; Nicola Giacchè; Roberto Pellicciari
Journal:  Antioxid Redox Signal       Date:  2021-03-17       Impact factor: 8.401

5.  LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.

Authors:  Cheng Xiang; Mao-Lin Zhang; Qun-Zi Zhao; Qiu-Ping Xie; Hai-Chao Yan; Xing Yu; Ping Wang; Yong Wang
Journal:  Oncotarget       Date:  2017-04-04

Review 6.  NAD+ homeostasis in renal health and disease.

Authors:  Kenneth M Ralto; Eugene P Rhee; Samir M Parikh
Journal:  Nat Rev Nephrol       Date:  2019-10-31       Impact factor: 28.314

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.